Covaxin's efficacy is 81%, claims Bharat Biotech
DTMT NETWORK
Bharat Biotech has claimed that it's Corona vaccine Covaxin has demonstrated an interim vaccine efficacy of 81% in its phase 3 clinical trials.
The company further added that the trials involved 25,800 subjects, the largest ever conducted in India, in partnership with ICMR.
